Journal article
Genomic Subtyping in Bladder Cancer.
- Jalanko T Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
- de Jong JJ Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Gibb EA Decipher Biosciences, Vancouver, Canada.
- Seiler R Department of Urology, University of Bern, Bern, Switzerland.
- Black PC Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. pblack@mail.ubc.ca.
- 2020-03-14
Published in:
- Current urology reports. - 2020
Bladder cancer
Genomic analysis
Immunotherapy
Molecular subtyping
Mutations
Neoadjuvant chemotherapy
Biomarkers, Tumor
Genomics
Humans
Mutation
Prognosis
Urinary Bladder Neoplasms
English
PURPOSE OF REVIEW
Molecular characterization of cancer allows us to understand oncogenesis and clinical prognosis as well as facilitates development of biomarkers and treatment. Our aim was to review the current literature on genomic characterization of bladder cancer, and how far we are in implementing genomics into clinical practice.
RECENT FINDINGS
Bladder cancers are molecularly diverse tumors with a high mutational rate. On molecular level, bladder cancer can be categorized into at least six subtypes called luminal-papillary, luminal-unstable, luminal non-specified, basal-squamous, neuroendocrine-like, and stroma-rich. These subtypes have characteristic genomic and transcriptomic profiles and appear to have different prognoses. Several molecular subtypes have been identified in bladder cancer. Prospective trials are underway to validate the applicability of genomic subtypes for clinical decision making. Further integrative analyses of genomic alterations, gene expression, epigenetics, and proteomics need to be performed before genomic subtyping can be attained in clinical practice.
Molecular characterization of cancer allows us to understand oncogenesis and clinical prognosis as well as facilitates development of biomarkers and treatment. Our aim was to review the current literature on genomic characterization of bladder cancer, and how far we are in implementing genomics into clinical practice.
RECENT FINDINGS
Bladder cancers are molecularly diverse tumors with a high mutational rate. On molecular level, bladder cancer can be categorized into at least six subtypes called luminal-papillary, luminal-unstable, luminal non-specified, basal-squamous, neuroendocrine-like, and stroma-rich. These subtypes have characteristic genomic and transcriptomic profiles and appear to have different prognoses. Several molecular subtypes have been identified in bladder cancer. Prospective trials are underway to validate the applicability of genomic subtypes for clinical decision making. Further integrative analyses of genomic alterations, gene expression, epigenetics, and proteomics need to be performed before genomic subtyping can be attained in clinical practice.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1007/s11934-020-0960-y
- PMID 32166460
- Persistent URL
- https://folia.unifr.ch/global/documents/127765
Statistics
Document views: 49
File downloads: